Featured Research

from universities, journals, and other organizations

Antipsychotic drugmakers target marketing dollars at D.C. Medicaid psychiatrists, study indicates

Date:
September 26, 2012
Source:
George Washington University
Summary:
The D.C. Department of Health has released a study by George Washington University School of Public Health & Health Services indicating the high levels of marketing by antipsychotic drug manufacturers to Medicaid psychiatrists in the District of Columbia.

The D.C. Department of Health (DOH) has released a study by George Washington University School of Public Health & Health Services (SPHHS) indicating the high levels of marketing by antipsychotic drug manufacturers to Medicaid psychiatrists in the District of Columbia.

Antipsychotics are one of the top-selling drug classes; In 2010, top antipsychotic manufacturers spent more than $25 million on marketing in Washington DC. Among 26 psychiatrists receiving at least $1000 from top antipsychotic manufacturers in 2010, 7 (27%) were Medicaid providers. Medicaid psychiatrists, however, received a disproportionate, share of industry largesse, receiving two-thirds (66%) of gifts and payments. In 2008 (the most recent data available),antipsychotic use by Medicaid recipients was especially high in the nation's capitol, with approximately 1 in 10 recipients receiving a prescription -- a rate five times higher than the total national population.

A large proportion of Medicaid recipients are children under the age of 18. Antipsychotics can cause sedation, weight gain, diabetes, and other adverse effects. Previous studies have shown a high rate of inappropriate off-label use (for conditions the FDA has not approved). Some adverse events may be more likely to occur in children and young adults.

Lead researcher Susan Wood, PhD, Associate Professor at SPHHS, said, "Pharmaceutical marketing affects which drugs are prescribed. Prescribing decisions can have a profound effect on both state coffers and population health."

"Antipsychotics are clearly being used in patients who are not psychotic," said Adriane Fugh-Berman, MD, collaborator on the report and Associate Professor of Pharmacology and Physiology at Georgetown University Medical Center.

The report is in fulfillment of AccessRx, the District of Columbia's 2006 law requiring public disclosure of pharmaceutical marketing expenditures spent on all health care providers by every pharmaceutical company that markets in the District. The DOH's Health Regulation and Licensing Administration commissioned the study by SPHHS on the 2010 data. The amounts paid by antipsychotic manufacturers to DC Medicaid and non-Medicaid psychiatrists are included in the report, along with the effects of the new public records on prescribing and marketing trends.

Access to the report is available on DOH's web site, http://doh.dc.gov/node/158762


Story Source:

The above story is based on materials provided by George Washington University. Note: Materials may be edited for content and length.


Cite This Page:

George Washington University. "Antipsychotic drugmakers target marketing dollars at D.C. Medicaid psychiatrists, study indicates." ScienceDaily. ScienceDaily, 26 September 2012. <www.sciencedaily.com/releases/2012/09/120926104228.htm>.
George Washington University. (2012, September 26). Antipsychotic drugmakers target marketing dollars at D.C. Medicaid psychiatrists, study indicates. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/09/120926104228.htm
George Washington University. "Antipsychotic drugmakers target marketing dollars at D.C. Medicaid psychiatrists, study indicates." ScienceDaily. www.sciencedaily.com/releases/2012/09/120926104228.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins